6037 |
Case 2. Anatomy vs. Physiology Approach for Complete Revascularization in ACS? |
Shamir R. Mehta |
Apr. 19. 24 |
6036 |
Case 1. Post-PCI FFR: Pressure Pullback Gradient to Predict Prognosis After Revascularization |
Carlos Collet |
Apr. 19. 24 |
6035 |
Update on the ALL-RISE Trial (Advancing Cath Lab Results With FFR-Angio Physiology Assessment) |
William F. Fearon |
Apr. 19. 24 |
6034 |
QFR for All Lesions and Patients? - Current Level of Evidence |
Niels Ramsing Holm |
Apr. 19. 24 |
6033 |
Synergetic Approach for Discordant Lesions Between FFR and Non-Hyperemic Indexes |
Jung-Min Ahn |
Apr. 19. 24 |
6032 |
FFR and IFR: Where Do We Stand Today? |
Nico Pijls |
Apr. 19. 24 |
6031 |
Long-term DOAC Management of AF and Stable CAD: Expectation on the EPIC-CAD Trial After the AFIRE Trial |
Gi-Byoung Nam |
Apr. 19. 24 |
6030 |
Don't Forget About Dual Pathway Inhibition: When DOAC Should Not Be Standard Treatment |
Dominick J. Angiolillo |
Apr. 19. 24 |
6029 |
Escalation and De-Escalation Strategy for CHIP-PCI Patients: The TAILORED-CHIP Trial |
Duk-Woo Park |
Apr. 19. 24 |
6028 |
De-Escalation Strategy of Antithrombotic Therapy: Why, in Whom, and How? |
Sripal Bangalore |
Apr. 19. 24 |